Navigation Links
Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
Date:12/9/2008

TORONTO, Dec. 9 /PRNewswire/ - Interface Biologics Inc. - a privately held developer of novel biomedical-polymers for use in implantable medical devices - is announcing that it has secured a $5mm financing round. Participating in the round were existing investors Covington Capital, VG Partners and BDC Capital. In connection with the financing, Lily Lam from Covington Capital is joining the Board of Directors and Thomas P. Reeves has been appointed the new President and CEO and is also joining the Board of Directors.

"We are fully committed to Interface Biologics and are excited about the continued commercialization opportunities for the Company in the near future. We're pleased to have Tom Reeves joining the Interface team and believe his broad leadership experience - most recently as President and COO of OccuLogix, a medical device company focused on treating age related diseases from the eye (NASDAQ) - will complement our existing scientific and technical expertise as we move into the clinical application and commercialization phase with many of the Company's novel polymer products," said Jeff Courtney, General Partner of VG Partners. "We are also excited to welcome Lily Lam, Vice President Investments, from Covington Capital to the Board of Directors."

"The fact that Interface has been able to raise a significant new round of financing in these difficult economic times is testament to the strength of the organization and its unique products in key applications and rich IP that crosses the spectrum of medical devices," said Tom Reeves, President and CEO of Interface Biologics, Inc. "I am pleased to be joining the Interface team and look forward to leading the team as we capitalize on the research and development work that is solidly established and execute on the commercialization of a number of the products in our portfolio."

About Interface Biologics: Interface Biologics is a biomaterials company based in Toronto, Canada, developing proprietary, nano-engineered biomedical-polymers for use in implantable medical devices. Our understanding of the interface between the human body and implantable biomaterials at the molecular level has driven the development of medical devices that are not only more biocompatible but also programmable for the delivery of more effective therapy.

About VG Partners: A premier Canadian private equity investment firm, VG Partners builds innovative companies into global successes. Since 1982, we have invested over $1.3 billion in almost 200 North American companies, working alongside business owners to maximize potential. The investment team provides a breadth of industry experience within technology, life sciences, industrial and consumer sectors, as well as a hands-on approach that is unparalleled. VG Partners is part of VenGrowth Private Equity Partners Inc. For more, visit www.vgpartners.com

About BDC Capital: BDC Venture Capital is a major venture capital investor in Canada, active at every stage of the company's development cycle, from seed through expansion, with a focus on technology-based businesses that have high growth potential and that are positioned to become dominant players in their markets.

About Covington Capital: Established in 1994, Covington Capital is one of Canada's largest providers of venture capital investment funds. Managing over $400 million in assets, Covington provides Canadians with the ability to access venture capital investment opportunities via their suite of retail venture capital product offerings.


'/>"/>
SOURCE Interface Biologics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
2. Savient Submits Biologics License Application (BLA) for pegloticase
3. Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.
4. Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy
5. DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
6. NuVasive Completes Acquisition of Osteocel Biologics Business
7. Pinnacle Biologics Announces Agreement With pharmexx to Expand Sales Support Activities in Key European Markets
8. Pinnacle Biologics Announces Opening of Executive Offices in Bannockburn, Illinois and the Addition of Sandra Miller to the Board of Directors
9. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
10. Pinnacle Biologics Announces Contract With Chiltern
11. Pinnacle Biologics Announces Logistics Services Agreement With the Movianto Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... 07, 2016 , ... A new study published in the ... treated, advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute for ... blood sampling may improve the value of a blood-based test.” The study was ...
(Date:12/7/2016)... 2016 Neogen Corporation (NASDAQ: NEOG ... Kephart as its chief science officer — a ... responsibilities at Neogen effective Jan. 1. Kephart ... agribusiness unit of Thermo Fisher Scientific, as well as ... His extensive industry experience also includes the management of ...
(Date:12/7/2016)... , Dec. 7, 2016 /PRNewswire/ - Zenith Capital Corp. ("Zenith" ... that will be presented at the Company,s Annual and Special ... of Shareholders will take place on Thursday, December 15, 2016 ... Glenn Hall (Room EC1040), 4825 Mount Royal Gate SW, ... (MST). A notice of meeting and management information circular, containing ...
(Date:12/7/2016)... Dec. 7, 2016  Biocom, the association for the ... below following passage of 21 st Century Cures legislation ... 30 by a 392-26 vote and in the Senate on ... attributed to Joe Panetta , president & CEO of ... give hope to millions of patients around the world. The ...
Breaking Biology Technology:
(Date:12/5/2016)... , Dec. 5, 2016  The Office ... today published "Can CT Scans Enhance or Replace ... the potential of supporting or replacing forensic autopsies ... CT scan. In response to recommendations ... is exploring using CT scans as a potential ...
(Date:11/30/2016)... Nov. 30, 2016  higi SH llc (higi) ... initiative targeting national brands, industry thought-leaders and celebrity ... respective audiences for taking steps to live healthier, ... in 2012, higi has built the largest self-screening ... 38 million people who have conducted over 185 ...
(Date:11/28/2016)... 28, 2016 "The biometric ... 16.79%" The biometric system market is in the ... the near future. The biometric system market is expected ... at a CAGR of 16.79% between 2016 and 2022. ... biometric technology in smartphones, rising use of biometric technology ...
Breaking Biology News(10 mins):